3:11
EORTC CLTF 2018 | CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma
Irving Weissman
9:02
iwNHL 2018 | Precision medicine in lymphoma
Anas Younes et al.
3:32
SOHO 2018 | ZUMA-1: updated data and future prospects
John Rossi
3:22
SOHO 2018 | The impact of MRD as a biomarker
Nathan Fowler
1:14
SOHO 2018 | Are biomarkers the future in Non-Hodgkin Lymphoma?
Nathan Fowler
2:53
SOHO 2018 | Follicular lymphoma: identifying high-risk patients
Nathan Fowler
3:12
EHA 2018 | Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny
2:03
ASCO 2018 | Trial updates in NHL: RELEVANCE, polatuzumab, TRANSCEND-NHL-001 & Hu5F9-G4
Nathan Fowler
1:32
ASCO 2018 | Choosing the best treatment for your follicular lymphoma patient
Nathan Fowler
3:53
ASCO 2018 | Results of RELEVANCE: frontline rituximab-lenalidomide for follicular lymphoma
Nathan Fowler
2:28
EHA 2018 | Preventing early disease progression in follicular lymphoma
John Seymour
3:21
EHA 2018 | RELEVANCE study: the R-squared regimen for follicular lymphoma
Wojciech Jurczak
2:27
BSH 2018 | Challenges within follicular lymphoma treatment
Wendy Osborne
1:34
BSH 2018 | Molecular-guided treatment of B-cell lymphomas
Jude Fitzgibbon
1:42
BSH 2018 | Precision medicine for B-cell lymphomas
Jude Fitzgibbon
6:38
EHA 2018 | Follicular lymphoma: is RELEVANCE relevant?
Frank Morschhauser
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals